Strong Pipeline and Book-to-Bill Ratio
The company reported a book-to-bill ratio of 1.02 times for the quarter and 1.14 times for the trailing 12 months, with a solid pipeline of opportunities expected to produce attractive book-to-bills for the remainder of the year.
Successful Cost Reduction Initiatives
Fortrea achieved a more than 8% reduction in permanent headcount over the last 12 months, leading to year-over-year growth in adjusted EBITDA and adjusted EPS for the first time since the spin. SG&A costs showed a 3% sequential reduction from Q4 2024.
Technological Innovations and AI Integration
The company is integrating AI tools like Microsoft Copilot across its operations to improve productivity, already observing more than a 50% increase in usage week-by-week.
Reaffirmed Guidance for 2025
Fortrea reaffirmed its guidance for the year, targeting revenues between $2.45 billion to $2.55 billion and adjusted EBITDA between $170 million to $200 million.
Recognition and Customer Satisfaction
Fortrea was named a leader in pharmacovigilance operations by Everest Group, and customer Net Promoter Scores continued to trend upwards, meeting Q1 targets.